Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H ...
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target EDB+FN is found overexpressed ...
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it ...
In mid-2026, Pyxis Oncology (PYXS) plans to present updated data from the ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC, which is expected to include additional patients and initial durability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results